603716 Thalys Medical Technology Group Corporation.
- 7.42
- -0.56-7.02%
Thalys Medical Technology Group Corporation. News
Saili Healthcare (603716.SH): Net profit of 3.156,800 yuan in the first quarter
On April 27, Ge Longhui Medical (603716.SH) released its report for the first quarter of 2024, achieving operating income of 485 million yuan, an increase of 9.24% over the previous year; net profit attributable to shareholders of listed companies was 3.156,800 yuan, net profit attributable to shareholders of listed companies was 9097 million yuan after deducting non-recurring profit and loss, with basic earnings of 0.02 yuan per share.
Saili Healthcare (603716.SH) announced first-quarter results, net profit of 3.156,800 yuan
According to the Zhitong Finance App, Saili Healthcare (603716.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 485 million yuan, an increase of 9.24% over the previous year; net profit attributable to shareholders of listed companies was 3.156,800 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 9097 million yuan; and basic earnings per share were 0.02 yuan.
Saili Healthcare (603716.SH): Shares were not repurchased in March
Gelonghui, April 1, 丨 Saili Healthcare (603716.SH) announced that in March 2024, the company did not buy back shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. As of March 31, 2024, the company has repurchased 2,070,000 shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. The repurchased shares account for 1.0282% of the company's total share capital. The highest transaction price of the repurchased shares is 6.59 yuan/share, the lowest transaction price is 5.37 yuan/share, and the total amount paid is RMB 12,976,843 (excluding transaction)
Saili Healthcare (603716.SH): cumulative repurchase of 1.0282% of the company's shares
Gelonghui, March 4, 丨 Saili Healthcare (603716.SH) announced that as of February 29, 2024, the company had repurchased 2,070,000 shares of the company's shares through centralized bidding transactions. The repurchased shares accounted for 1.0282% of the company's total share capital. The highest transaction price for the repurchase was 6.59 yuan/share, the minimum transaction price was 5.37 yuan/share, and the total amount paid was RMB 12,976,843 (excluding transaction fees).
Saili Healthcare (603716.SH): Cumulative repurchase of 1.0282% of shares as of February 8
Gelonghui, Feb. 8, 丨 Saili Healthcare (603716.SH) announced that as of February 8, 2024, the company had repurchased 2.07 million shares of the company through centralized bidding transactions. The repurchased shares accounted for 1.0282% of the company's total share capital, an increase of 0.2633% compared with the previous disclosure. The highest transaction price for the newly purchased shares was 5.79 yuan/share, and the minimum transaction price was 5.37 yuan/share. The total amount paid was RMB 129.768 million (excluding transaction fees).
Saili Healthcare (603716.SH): 1.54 million shares repurchased for the first time
On February 6, 2024, Gelonghui Healthcare (603716.SH) announced that on February 6, 2024, the company repurchased 1.54 million shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.7649% of the company's total share capital. The highest price of the repurchase transaction was 6.59 yuan/share, the lowest price was 6.42 yuan/share, and the total capital paid was RMB 9,930,453 (excluding transaction fees).
Saili Healthcare (603716.SH): Plans to spend 10 million yuan to 20 million yuan to buy back shares
On February 5, Gelonghui Medical (603716.SH) announced that the company plans to repurchase the company's shares through centralized bidding transactions; the total repurchase capital shall not be less than RMB 10 million (inclusive) and not more than RMB 20 million, and the repurchase price shall not exceed RMB 12.16 per share (inclusive).
Saili Healthcare (603716.SH): Pre-loss of 115 million yuan to 150 million yuan in 2023
Gelonghui, January 30, 丨 Saili Healthcare (603716.SH) announced the 2023 annual performance pre-loss announcement. It is estimated that net profit attributable to shareholders of listed companies will be -115 million yuan to -150 million yuan in 2023; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss in 2023 is -110 million yuan to -145 million yuan.
Celi Healthcare (603716.SH): The SPD projects of Bishan Second People's Hospital and Bishan Maternal and Child Health Hospital have been launched
Gelonghui November 23|Celi Healthcare (603716.SH) said at the performance briefing that in February 2022, the company signed the Chongqing Bishan Regional SPD construction project with the Chongqing Bishan District People's Government, which mainly includes the construction of projects such as Saili Healthcare's regional lean hospital management platform, regional testing center, harmless treatment of in-hospital medical waste, equipment management cloud service platform, and Internet hospital. Up to now, the SPD projects of Bishan Second People's Hospital and Bishan Maternal and Child Health Hospital have been launched, the key departments of the Bishan People's Hospital SPD project have been launched, and the Bishan Traditional Chinese Medicine Hospital SPD project is under active construction, Chongqing
Seri Healthcare (603716.SH): Net loss of 5.345,200 yuan in the third quarter
Glonghui, Oct. 26, 丨 Saili Healthcare (603716.SH) announced its report for the third quarter of 2023. Revenue for the reporting period was 519 million yuan, down 15.34% from the previous year; net profit attributable to shareholders of listed companies - 5.345,500 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 5155,800 yuan; basic earnings per share - 0.03 yuan/share.
Seri Medical (603716.SH): The preparation of the toxicology batch pilot sample has now been completed
Glonghui, Oct. 20 | Saili Medical (603716.SH) said on the investor interactive platform that it has now completed the preparation of the toxicology batch pilot test samples. If everything progresses smoothly, it is expected that the IND clinical approval application will be submitted before the end of the year.
Seri Healthcare (603716.SH): Efforts are being made to create a model for regional SPD projects with multiple business models and high-quality projects represented by Bishan, Chongqing, etc.
Glonghui, Oct. 10, 丨 Saili Medical (603716.SH) said at the semi-annual performance briefing that the company is based on the unique “SPD+CDSS+DRGS/DIP” solution, and according to the “broad market+regionalized model” raft strategy, further explores the superposition of multiple business models based on regionalized SPD projects (SPD+IVD+ICL+RMLC+ medical waste treatment+medical equipment maintenance). Currently, the company has used the southwest market as a pilot project base for implementing the above strategies, and is focusing on building regionalization represented by Bishan, Chongqing, etc. The SPD project overlaps with multiple business models
Seri Healthcare (603716.SH): “Seri Convertible Bonds” is expected to trigger downward revision conditions in the conversion price
Glonghui, September 22, 丨 Seri Healthcare (603716.SH) announced that from September 11, 2023 to September 22, 2023, the closing price of the company's stock for 10 out of 30 consecutive trading days was lower than 85% of the current conversion price (14.43 yuan/share), which is expected to trigger the “Seri Bonds” conversion price correction conditions.
Shengang Securities: Driven by both policy and market, the SPD industry ushered in a new round of development opportunities
Currently, the market is in a period of explosion
Seri Healthcare (603716.SH): Net profit of 1.53 million yuan in the first half of the year fell 8.9% year on year
Glonghui, August 29丨Celi Healthcare (603716.SH) announced its semi-annual report. Operating income was 1.01 billion yuan, down 12.09% year on year, net profit was 1.53 million yuan, down 8.9% year on year, net profit was 1.53 million yuan, down 8.9% year on year, after deducting non-net loss of 6.06 million yuan, converted to losses year on year, and basic earnings per share were 0.0075 yuan.
Open Source Securities: SPD may be a powerful driver for improving hospital integrity, and the penetration rate of the industry is expected to increase rapidly
The SPD system establishes a transparent drug circulation record by tracking the flow and inventory of drugs in the supply chain in real time.
4-Board Force Healthcare (603716.SH): Production and operation are normal, there is no important information not disclosed
According to the Zhitong Finance App, Celi Healthcare (603716.SH) announced that the total daily closing price deviation value of the company's shares during 2 consecutive trading days on August 10 and August 11, 2023 was more than 20%. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules”, this is a situation where stock trading fluctuates abnormally. According to the company's own inspection, at present, all of the company's production and operation activities are normal, there have been no major adjustments to the market environment or industry policies, and the internal production and operation order is normal. There are no major matters affecting abnormal fluctuations in the trading price of the company's shares, and there is no material information that should have been disclosed but not disclosed.
3-Board Power Healthcare (603716.SH): Judging from the current competitive situation in the SPD industry, there will be more entrants participating
According to the Zhitong Finance App, Celi Healthcare (603716.SH) announced that as of August 10, 2023, the closing price of the company's stock was 13.21 yuan/share. After hitting abnormal fluctuations on August 9, 2023, the company's stock rose and stopped again on August 10, and the stock price fluctuated greatly. In addition, the company's results for 2022 and the first quarter of 2023 were at a loss. Investors are kindly requested to pay attention to investment risks and make rational decisions. According to reports, recently the market is paying more attention to the company's medical consumables intensive operation service (SPD business). The SPD business is centered on a “smart supply chain”
Glonhui Announcement Highlights | China Unicom: Net profit in the first half of the year increased 13.7% year-on-year to 5.444 billion yuan, with proposed dividends of about 2,491 billion yuan; mass media: net profit increased 59.00% to 2,231 billion yuan
[Performance Focus] China Unicom (600050.SH): Net profit for the first half of the year increased 13.7% year on year to 5.444 billion yuan and plans to pay about 2,491 billion yuan. China Unicom (600050.SH) announced the 2023 semi-annual report. The reporting period achieved operating income of 191,833 billion yuan, up 8.8% year on year; net profit attributable to shareholders of listed companies was 5.444 billion yuan, up 13.7% year on year; basic earnings per share 0.174 yuan. First half of the year company
2-link cell therapy (603716.SH): Subsidiary SPD and IVD business, production and development of coagulation-related production reagents, etc. are progressing normally
According to the Zhitong Finance App, Celi Healthcare (603716.SH) announced that the total deviation value of the price increase at the closing price of the company's stock trading for 3 consecutive trading days (August 7, August 8, and August 9, 2023) was an abnormal fluctuation in stock trading. According to the company's own investigation, at present, all of the company's production and operation activities are normal. There have been no major adjustments to the market environment or industry policies. The company's SPD and IVD business, production and development of coagulation-related production reagents, etc. is progressing normally, and the internal production and operation order is normal. There are no major issues affecting abnormal fluctuations in the trading price of the company's shares, and there is no response
Analysis
Price Target
No Data
